Getein Biotech, Inc. (stock code:603387), estal a fully integrated in vitro diagnostic company that researches and develops, manufactures, fibutes a broad range of innovative diagnostic test kits in point-of-care testing (POCT). In July 2017, Getein Biotech got listed on the main board of the Shanghai Stock Exchange. With great contribution of our advanced R&D center and 19-year continuous development, Getein Biotech has developed 8 technology platforms, including Point-of-Care Testing (POCT), clinical chemistry, chemiluminescence, hematology, coagulation, urinalysis, molecular diagnostics and raw materials for diagnostic reagents, covering fields of cardiovascular disease, kidney injury, diabetes mellitus, gestation, infectious disease, cancer, etc..